|
HER3, PI3K, and JAK2 pathway activation on reverse phase protein microarray (RPMA) in HER2-amplified residual disease (RD) refractory to preoperative chemotherapy plus trastuzumab (H), lapatinib (L), or both (HL). |
|
|
|
Consulting or Advisory Role - bioTheranostics |
|
|
No Relationships to Disclose |
|
|
Employment - Theranostics Health |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Theranostics Health |
|
|
Employment - Foundation Medicine |
|
|
Employment - Foundation Medicine |
|
|
No Relationships to Disclose |